From the Duke Clinical Research Institute, Durham, NC (A.C.F., P.M., M.W.S., W.S.J., S.V.); Division of Cardiology (A.C.F., J.K.H., W.S.J., S.V.) and Division of Cardiovascular and Thoracic Surgery (G.C.H.), Duke University, Durham, NC; Division of Cardiology, Mayo Clinic, Rochester, MN (D.R.H.); Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City (D.J.C.); Division of Cardiothoracic Surgery, Emory University, Atlanta, GA (V.H.T.); The Heart Hospital Baylor Plano, TX (M.J.M.); and Inova Heart and Vascular Institute, Falls Church, VA (M.W.S.).
Circ Cardiovasc Interv. 2017 Oct;10(10). doi: 10.1161/CIRCINTERVENTIONS.117.005456.
Peripheral artery disease (PAD) is associated with increased cardiovascular mortality, and PAD risk factors overlap with those for aortic stenosis. The prevalence and outcomes associated with PAD in a population undergoing transcatheter aortic valve replacement (TAVR) are unknown.
Using the Society of Thoracic Surgeons/Transcatheter Valve Therapy Registry linked to Medicare claims data, we identified patients ≥65 years old undergoing TAVR from 2011 to 2015. We calculated hazard ratios for 1-year adverse outcomes, including mortality, readmission, and bleeding, for patients with PAD compared with those without, adjusting for baseline characteristics and postprocedure medications. Analyses were performed separately by access site (transfemoral and nontransfemoral). Of 19 660 patients undergoing transfemoral TAVR, 4810 (24.5%) had PAD; 3730 (47.9%) of 7780 patients undergoing nontransfemoral TAVR had PAD. In both groups, patients with PAD were significantly more likely to have coronary and carotid artery diseases. At 1-year follow-up, patients with PAD undergoing TAVR via transfemoral access had a higher incidence of death (16.8% versus 14.4%; adjusted hazard ratio, 1.14; =0.01), readmission (45.5% versus 42.1%; hazard ratio, 1.11; <0.001), and bleeding (23.1% versus 19.7%; hazard ratio, 1.18; <0.001) compared with patients without PAD. Patients with PAD undergoing TAVR via nontransfemoral access did not have significantly higher rates of 1-year mortality or readmission compared with patients without PAD.
PAD is common among patients undergoing commercial TAVR via transfemoral and nontransfemoral access. Among patients undergoing transfemoral TAVR, PAD is associated with a higher incidence of 1-year adverse outcomes compared with absence of PAD.
URL: http://www.clinicaltrials.gov. Unique identifier: NCT01737528.
外周动脉疾病(PAD)与心血管死亡率增加有关,其风险因素与主动脉瓣狭窄的风险因素重叠。在接受经导管主动脉瓣置换术(TAVR)的人群中,PAD 的患病率和结局尚不清楚。
我们利用胸外科医师学会/经导管瓣膜治疗登记处与医疗保险索赔数据的链接,确定了 2011 年至 2015 年期间接受 TAVR 的年龄≥65 岁的患者。我们计算了与无 PAD 患者相比,有 PAD 患者的 1 年不良结局(包括死亡率、再入院和出血)的风险比,并根据基线特征和术后药物进行了调整。分别按入路(经股和非经股)进行分析。在 19660 例接受经股 TAVR 的患者中,4810 例(24.5%)患有 PAD;在 7780 例接受非经股 TAVR 的患者中,3730 例(47.9%)患有 PAD。在两组中,有 PAD 的患者更有可能患有冠状动脉和颈动脉疾病。在 1 年随访时,经股入路 TAVR 合并 PAD 的患者死亡率较高(16.8%比 14.4%;调整后的风险比,1.14;=0.01),再入院率较高(45.5%比 42.1%;风险比,1.11;<0.001),出血率较高(23.1%比 19.7%;风险比,1.18;<0.001)。与无 PAD 的患者相比,经非股入路 TAVR 合并 PAD 的患者 1 年死亡率或再入院率无显著升高。
经股和非股入路接受商业 TAVR 的患者中,PAD 很常见。在接受经股 TAVR 的患者中,与无 PAD 相比,PAD 与 1 年不良结局的发生率更高相关。